利伐沙班与低分子肝素钠治疗门静脉血栓的临床效果

Abstract
Figure/Table
References (22)
Related Citation (14)

Download: PDF (0 KB) HTML (38 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To explore the effect of Rivaroxaban and Low Molecular Weight Heparin Sodium in the treatment of portal vein thrombosis.Methods A total of 72 patients with portal vein thrombosis who received treatment in the General Surgery Department of the Third People′s Hospital of Jiujiang City from June 2019 to June 2020 were selected as the research subjects.They were divided into group A(oral administration of Rivaroxaban at 72 hours before surgery),group B(oral administration of Rivaroxaban at 72 hours after surgery),and group C(subcutaneous injection of Low Molecular Weight Heparin Sodium at 72 hours after surgery)by random number table method,with 24 patients in each group.After treatment,the total incidence of adverse events,indicators related to portal vein recanalization and the total incidence of thrombus events of the three groups were compared.Results After treatment,the total incidence of adverse events in group A was higher than that in group B and C,with statistical significance(P＜0.05).There was no significant difference in the total incidence of adverse events between group B and group C(P＞0.05).After treatment,D-dimer were lower than those in group B and C,prothrombin time(PT)and activated partial prothrombin time(APTT)in group A were shorter than those in group B and C,and fibrinogen(FIB)value was higher than that in group B and C,the differences were statistically significant(P＜0.05).After treatment,there was no significant difference in INR value among group A,B and C(P＞0.05).There were no significant differences in D-dimer,PT,APTT and INR values between group B and C(P＞0.05).After treatment,the total incidence of thrombus events in group A was lower than that in group B and C,with statistical significance(P＜0.05).There was no significant difference in the total incidence of thrombus events between group B and group C(P＞0.05).Conclusion In the process of clinical treatment of portal vein thrombosis,there was no significant difference in the anticoagulant effect of patients treated with Rivaroxaban or Low Molecular Weight Heparin Sodium at 72 h after operation.However,patients treated with Rivaroxaban at 72 h before surgery was helpful to reduce the incidence of thrombus in patients.There was no significant difference in the incidence of thrombosis among patients treated with Rivaroxaban or Low Molecular Weight Heparin Sodium at 72 h before surgery.On the other hand,patients treated with Rivaroxaban at 72 h before surgery was more helpful for portal vein recanalization.

Key words： Rivaroxaban Low Molecular Weight Heparin Sodium Portal vein thrombosis Coagulation index Thrombosis rate

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	WAN Dong-qiang
	WANG Huo-ping
	HU Hai-yang
	HU Wen-feng

Cite this article:

WAN Dong-qiang,WANG Huo-ping,HU Hai-yang, et al. Clinical effect of Rivaroxaban and Low Molecular Weight Heparin Sodium in the treatment of portal vein thrombosis[J]. 中国当代医药, 2021, 28(17): 162-165.

URL:

http://dangdaiyiyao.com/EN/ OR http://dangdaiyiyao.com/EN/Y2021/V28/I17/162

[1]	沈晓震，陈有芬，郑艳峰.利伐沙班联合低分子肝素对脊柱创伤术后血流变及凝血功能的影响[J].中国药物与临床，2018，18（4）：569-570.
[2]	冯湧，马文泽，于学超，等.利伐沙班和低分子肝素预防老年关节置换术后下肢深静脉血栓的比较研究[J].现代药物与临床，2018，33（2）：P376-381.
[3]	邢贞武，余德涛，邢祯全，等.利伐沙班与低分子肝素钙预防全髋关节置换术后深静脉血栓的效果比较[J].中国药房，2017，28（23）：3247-3250.
[4]	吴怀球，张卫东，彭敏恋，等.利伐沙班在急性中危肺血栓栓塞合并下肢深静脉血栓患者治疗中的作用[J].实用医学杂志，2017，33（22）：3802-3806.
[5]	蔡亮，丁勇，周旻，等.利伐沙班与传统抗凝药物在80 岁以上静脉血栓栓塞症患者中的有效性与安全性对比[J].中国临床医学，2019，26（2）：118-122.
[6]	梁法瑞，韦标方.利伐沙班和低分子肝素预防老年股骨粗隆间骨折术后深静脉血栓效果比较[J].青岛大学医学院学报，2017，53（5）：565-567.
[7]	王晓永.低分子肝素与利伐沙班在脊柱手术中的作用及对术后DVT 的预防效果[J].颈腰痛杂志，2018，39（2）：233-234.
[8]	杨霞，董淑杰，翟所迪.利伐沙班治疗深静脉血栓有效性和安全性的Meta 分析[J].中国药学杂志，2017，52（21）：1948-1952.
[9]	党永康，姜学超，杨柳，等.利伐沙班在急性肺动脉栓塞介入治疗中的应用[J].中华普通外科杂志，2018，33（10）：853-856.
[10]	杨婕，温华，马冰，等.7 种新型口服抗凝药预防全髋，膝关节置换术后静脉血栓栓塞症的网状Meta 分析[J].药学实践杂志，2018，36（6）：65-70.
[11]	王永刚，史振宇，符伟国，等.利伐沙班和低分子肝素用于部分实体恶性肿瘤合并静脉血栓栓塞症抗凝的疗效分析[J].复旦学报（医学版），2018，45（1）：57-61.
[12]	白云飞，房体刚，孙瑞.老年全髋关节置换后利伐沙班与低分子肝素预防深静脉血栓形成及失血情况对比[J].中国组织工程研究，2018，22（15）：2303-2308.
[13]	李鑫，茆玲，林敏，等.利伐沙班与低分子肝素对髋膝关节置换术后下肢深静脉血栓预防的应用评价[J].蚌埠医学院学报，2018，43（12）：31-34.
[14]	李建，邱冰，甄东，等.利伐沙班与低分子肝素钙在髋膝关节置换术后预防静脉血栓疗效性和安全性的Meta 分析[J].中国骨与关节杂志，2018，7（4）：277-282.
[15]	赵振林，赵思蓉，刘康峰，等.颅内静脉窦血栓患者行介入溶栓、抗凝联合治疗的临床效果[J].中国医药科学，2019，9（14）：197-200.
[16]	李占鲁，王敏，赵炎波，等.服用新型口服抗凝药合并冠状动脉粥样硬化性心脏病患者冠状动脉介入治疗围术期抗栓策略的探讨[J].中国现代医生，2020，58（30）：46-49.
[17]	余芳，李志华，付霞丽，等.补阳还五汤联合利伐沙班预防髋部周围骨折术后深静脉血栓形成的疗效分析[J].四川中医，2018，36（2）：140-143.
[18]	王丽亮，金津，杨洋，等.利伐沙班对比低分子肝素预防髋骨骨折患者发生静脉血栓的有效性和安全性的Meta分析[J].中国药房，2019，30（1）：126-130.
[19]	莫华贵，黄远翘，罗裕强，等.阿司匹林低分子肝素钠利伐沙班预防膝关节置换术后下肢深静脉血栓形成研究[J].河北医学，2020，26（4）：533-537.
[20]	范惠双，谭志斌，曾汉强，等.利伐沙班，脉血康联合腔内介入治疗髂股静脉血栓形成后综合征疗效及对凝血-纤溶功能和血管内皮功能的影响[J].现代中西医结合杂志，2020，29（10）：1063-1066.
[21]	李扬会，刘政，郝清智，等.利伐沙班治疗妊娠期深静脉血栓形成合并HIT 1 例报告[J].中国中西医结合外科杂志，2019，25（4）：619-621.
[22]	刘会霞，邱光英.利伐沙班和低分子肝素在治疗癌症并发静脉血栓栓塞症中的效果[J].中华肿瘤防治杂志，2019，26（S1）：162，164.